Cholesterol is an essential structural component of mammalian cells, although elevated concentrations of cholesterol in the human body are linked to atherosclerotic disease. In this context, monitoring physiological cholesterol concentrations is of great interest in medical fields and the concept of producing electrical energy from cholesterol is interesting. In this work, we report the bioelectrocatalytic oxidation of cholesterol with the use of nicotinamide adenine dinucleotide-(NAD) dependent cholesterol dehydrogenase (ChDH) as an alternative enzyme to the commonly-used cholesterol oxidase (ChOx) in bioelectronic applications. To achieve bioelectrocatalytic cholesterol oxidation, ChDH was combined with diaphorase (DH) in a bilayer fashion, whereby DH acts as an intermediary enzyme to facilitate NADH oxidation at a ferrocene redox polymer. Characterization of the resulting bioanode identifies a linear cholesterol response range from 5 μM to 200 μM, with an associated sensitivity of 60.12 mA cm −2 M −1 . Furthermore, an O 2 -reducing biocathode incorporating bilirubin oxidase (BOx) was combined with the cholesterol bioanode into a complete cholesterol/O 2 membrane-less enzymatic fuel cell (EFC).
Enzymatic fuel cells (EFCs) are devices that employ oxidoreductases as redox biocatalysts to enable the production of electrical energy from energy-dense substrates under mild conditions. Most of these substrates, such as sugars and linear alcohols (glucose, maltose, lactose, ethanol, methanol and fructose), are considered as alternative fuels with high energy densities. [1] [2] [3] [4] [5] [6] [7] [8] During recent decades, an exhaustive list of EFCs can be found in the literature aiming to exploit these alternative sources or to develop self-powered electrochemical biosensors working in vitro or in vivo. 6 In EFCs, the fuels undergo bioelectrocatalytic oxidation at the anode operating commonly with flavin adenine dinucleotide-dependent (FAD) oxidases and dehydrogenases as well as nicotinamide adenine dinucleotidedependent (NAD) dehydrogenases. 5, [9] [10] [11] Metalloenzymes, such as laccases, bilirubin oxidase and peroxidase, are generally used at the cathode of EFCs allowing the bioelectrocatalytic reduction of O 2 or peroxides to H 2 O. [12] [13] [14] [15] In addition to carbohydrates, other types of enzyme substrates have been reported as fuels such as alkanes, carboxylic acids, and other organic molecules. 1, 16, 17 Cholesterol, a sterol lipid, is a potential fuel for EFCs that can be oxidized to cholest-4-ene-3-one by some oxidases and dehydrogenases. This waxy fat-like substance is an essential structural component of all mammalian cell membranes and it is an important precursor for the biosynthesis of steroid hormones and bile acids. 18 On the other hand, high concentrations of total cholesterol in human plasma (>5.2 mM or 200 mg/dL) has been linked with heart diseases and strokes. 19 In this context, many reports focusing on the development of electrochemical cholesterol biosensors have been described over the last decade. 18 Most of these electrochemical biosensors use the FAD-dependent cholesterol oxidase (ChOx), which is able to oxidize cholesterol using O 2 as an electron acceptor resulting in the production of hydrogen peroxide (H 2 O 2 ). H 2 O 2 is subsequently quantified at an electrode surface. [20] [21] [22] [23] Sekretaryova et al. have reported a single-enzyme self-powered biosensor based on an EFC working with ChOx at both the anode and cathode powered by the same substrate. This EFC is able to reach a maximum power density of 11.4 μW cm −2 at 53 mV which is enough to power an electrochemical display. 20 Most reported bioelectrodes employing ChOx are based on the electro-oxidation or electro-reduction of H 2 O 2 , which has been shown to act as an inhibitor to commonly-used O 2 -reducing cathodic enzymes (laccase and bilirubin oxidase). 12 Thereby, the production of H 2 O 2 can affect the performance and stability of EFCs. It is also important to note that biosensors using ChOx to quantify cholesterol as a function of H 2 O 2 are dependent on and limited by the availability of O 2 , which can affect the reproducibility of sample analysis. Additionally, most H 2 O 2 detection strategies leave devices susceptible to interference from chemicals commonly found in the bloodstream, such as acetaminophen and ascorbate. Such constraints are a limitation for the development of EFCs and implantable self-powered biosensors. NAD-dependent cholesterol dehydrogenase (ChDH) is an alternative enzyme to ChOx that could be applied in biosensors and assays to determine total and free cholesterol concentrations. ChDH is also able to catalyze the oxidation of cholesterol to cholest-4-ene-3-one although it employs NAD + , a soluble diffusive redox cofactor, as an electron acceptor to produce NADH. Furthermore, ChDH does not utilize O 2 as its electron acceptor, thus, catalysis takes place in the absence of O 2 and H 2 O 2 is not produced in the presence of O 2 .
Redox mediators are generally used as electron shuttles at the anode in order to mediate and facilitate electron transfer between enzymatic cofactors (e.g. FAD and NAD) and electrodes. While mediators can be used in solution (diffusive), they are most effective when immobilized with the enzyme in a redox polymer film at the electrode surface. Ferrocene and osmium polymers have frequently been used as redox polymers for mediated electron transfer (MET) with FADdependent enzymes. 12, [24] [25] [26] The use of redox mediators, however, is sometimes limited by the accessibility of FAD that is deeply-buried in the protein core.
MET with FAD-dependent ChOx has been reported with the use of a phenothiazine, but remains limited in terms of efficiency and sensitivity for EFC and biosensor development. 20, [27] [28] [29] This fact could explain the fact that bioelectrodes working with ChOx are almost exclusively based on the electro-oxidation or electro-reduction of H 2 O 2 . NAD-dependent enzymes, on the other hand, typically make H3025 use of alternative mediators and electrocatalysts, such as phenothiazines (methylene blue, methylene green, thionine and toluidine blue). Their use lowers the overpotential required for NADH oxidation at common electrode surfaces (such as carbon) and prevents the formation of radical species (e.g., NAD +• ), while reducing interferences from high applied oxidation potentials. 30 Dimethylferrocenemodified linear poly(ethylenimine) (FcMe 2 -LPEI) is a redox polymer that has been shown to afford efficient MET between several FADdependent enzymes and electrodes, facilitating the yield of high current densities.
5,10,31 FcMe 2 -LPEI cannot efficiently oxidize NADH, although the combination of NAD-dependent enzymes with an intermediary enzyme (diaphorase, DH) can overcome this limitation. DH is an FAD-dependent enzyme able to catalyze the oxidation of NADH using ferrocene as an electron acceptor. This enzyme has been used in EFCs to facilitate electron transfer from NAD-dependent enzymes to redox mediators. 32, 33 Thus, we proposed the co-immobilization of ChDH and DH within the FcMe 2 -LPEI redox polymer, facilitating an architecture that is able to amperometrically quantify cholesterol independent of H 2 O 2 production (Eqs. 1-3).
2FcMe 2 → 2FcMe 2
Herein, we report a membrane-less cholesterol/O 2 EFC that couples a cholesterol-oxidizing bioanode with an O 2 -reducing biocathode (incorporating bilirubin oxidase (BOx)) (Scheme 1). Such a device is anticipated to be useful for the development of implantable self-powered cholesterol biosensors or powering other medical devices. To facilitate the mediated oxidation of cholesterol at an electrode surface independent of O 2 , a bilayer immobilization approach was adopted.
The bottom layer consisted of DH immobilized within the FcMe 2 -LPEI redox polymer, where it was expected that DH would oxidize NADH and use the redox polymer as an electron acceptor. Then, the ChDH was immobilized in a covering layer by covalent crosslinking with another polymer (C 8 -LPEI, a redox-silent counterpart polymer to FcMe 2 -LPEI) on top of the DH/FcMe 2 -LPEI layer. BOx cathodes were then prepared using a previously-reported DET bioelectrode architecture. 12 Cholesterol/O 2 EFCs were assembled and characterized on their ability to generate electrical energy from the oxidation of cholesterol. The EFCs were evaluated in a buffered cholesterol solution as well as human serum (which naturally contains free cholesterol). EFCs configuration were evaluated in buffer at pH 7.5 and in human serum (which contains free cholesterol). A power density of 20.3 ± 0.5 μW cm −2 and an open circuit potential of 592 ± 5 mV were obtained with 5 mM of free cholesterol in buffer, while 9.02 μW ± 0.54 and 428.7 mV ± 5.4 were obtained with standard free cholesterol in human serum (∼1-2 mM free cholesterol). This cholesterol EFC presents a promising configuration for converting cholesterol in biological fluids into electrical energy and the development of a self-powered cholesterol sensor.
Experimental
Chemicals.-Cholesterol dehydrogenase (ChDH, Nocardia species, ≥18 U mg-1, E.C.:1.1.1.x (not yet registered)), Triton X-100, tetrabutylammonium bromide (TBAB), Nafion perfluorinated resin, human serum (from USA, sterile-filtered, male AB) and glutaraldehyde were purchased from Sigma-Aldrich (USA) and used as received. Diaphorase (DH) (Microorganism, ≥500 U mg-1, E.C.:1.6.99.3 and bilirubin oxidase (BOx, Myrothecium species, ≥1.2 U mg-1, E.C.:1.3.3.5) were a gift from Amano Enzymes Inc. (Japan) and used as received. Cholesterol was purchased from Alfa Aesar and used as received. Citric acid (monohydrate) and sodium phosphate (dibasic) were purchased from Fisher Scientific. β-Nicotinamide adenine dinucleotide (NAD + ) and β-Nicotinamide adenine dinucleotide, reduced form, disodium salt (NADH) were supplied by Research Products International Corp. Toray carbon paper (TGP-H-060, non-wet-proofed) was purchased from Fuel Cell Earth. Ethylene glycol diglycidyl ether (EGDGE) was purchased from Polysciences, Inc. Solutions were prepared using deionized (DI) water taken from a Millipore Type 1 (Ultrapure) Milli-Q system (18.2 M cm −1 ). All other chemicals were purchased from Sigma-Aldrich (USA).
Preparation of cholesterol solutions.-Cholesterol solutions of 10 and 15 mM were prepared with the following procedure. Solid cholesterol was stirred and heated (around 70
• C) with 10% or 15% Triton X-100. Citrate/phosphate buffer (100 mM, pH 7.5) previously heated up was mixed with the solid cholesterol/Triton X-100 mixture. The resulting solution was stirred and allowed to cool to room temperature before use.
Electrochemical methods.-All electrochemical measurements were conducted on a CH Instrument Inc. model 660e potentiostat at room temperature (19) (20) (21) • C). Experiments were conducted in 100 mM phosphate/citrate buffer (pH 7.5) containing 10% v/v Triton X-100 using a three-electrode setup that included a Toray carbon paper electrode (paraffin wax-coated) as the working electrode, a saturated calomel reference electrode (SCE) and a platinum mesh counter electrode. EFCs were characterized by recording the open circuit potential for 10 min, immediately followed by galvanostatic discharge with a current ramp-rate of 0.5 μA s −1 until short circuit. All cyclic voltammograms are presented using the polarographic notation (reductive currents plotted as positive values).
Enzymatic activity assays and denatured enzyme controls.-Enzymatic activity assays were performed to evaluate the activities of ChDH and DH before immobilization. Specific activity assays were performed in 100 mM phosphate/citrate buffer (pH 7.5) containing 10% v/v Triton X-100, to mimic the conditions of electrochemical evaluation. ChDH activity was evaluated by following the production of NADH at 340 nm in the presence of 10 mM NAD + and 10 mM cholesterol, yielding a specific activity of 12.8 ± 0.4 U mg −1 solid. Similarly, DH activity was evaluated within the same buffer, where NADH (2 mM) was the electron donor and dichlorophenolindophenol (0.04 mM) was used as the electron acceptor. The specific activity of DH was determined to be 30.2 ± 1.1 U mg −1 solid. Denatured/inactivated enzyme control samples (ChDH and DH) were prepared by heating aliquots of the enzymes to 100
• C for 1 h.
Preparation of bioelectrodes.-Dimethylferrocene-modified linear poly(ethylenimine) (FcMe 2 -LPEI), octyl-modified linear poly(ethylenimine) (C 8 -LPEI), anthracene-modified multi-walled carbon nanotubes (AcMWCNTs) and TBAB-modified Nafion (TBABNafion) were prepared as previously reported. 5, 15, 34 Toray carbon paper electrodes were cut and coated with paraffin wax to yield an exposed geometric surface area of 1 cm 2 . Bilayer bioanodes (ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI) were prepared by first casting the DH/FcMe 2 -LPEI layer. The bottom DH/FcMe 2 -LPEI layer was prepared by mixing 21 μL of FcMe 2 -LPEI (10 mg ml −1 ), 9 μL of DH (15 mg ml −1 ) and 1.125 μL of 10% v/v EGDGE. This mixture was diluted with 93.4 μL water and 35 μL was drop-casted on a Toray carbon paper electrode. The resulting electrode was dried under positive airflow overnight. The covering ChDH/C 8 -LPEI layer was prepared from a mixture containing 105 μL of C 8 -LPEI (10 mg ml −1 ), 45 μL of ChDH (45 mg ml −1 ) and 1.575 μL of a glutaraldehyde solution (62.5 mM). After vortex mixing, 35 μL of the final mixture was drop-casted onto a Toray carbon paper electrode on top of the previously-dried layer of DH/FcMe 2 -LPEI, and dried under positive airflow for 1 h at room temperature.
Biocathodes were prepared by mixing BOx (20 mg mL −1 citrate/phosphate buffer, 100 mM, pH 7.5) with 7.5 mg of Ac-MWCNTs. The suspension was vortex mixed (1 min) and sonicated (15 seconds) for 4 successive cycles. Then, 25 μL of TBAB-Nafion was added to the slurry, followed by one final vortex/sonication cycle (5 cycles in total). The final mixture was divided evenly between 3 Toray carbon paper electrodes. The electrodes were dried under positive airflow for 1 h at room temperature. After 1 h the other side of the electrode was painted with the mixture again and dried for an additional hour.
Results and Discussion
Bioanode characterization.-In order to confirm the mediated enzymatic bioelectrocatalytic oxidation of cholesterol by the bilayer bioanode (consisting of ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI), characterizations were performed in citrate/phosphate buffer at pH 7.5 supplemented with 10 mM cholesterol in the presence and absence of 5 mM NAD + (Figure 1 ). The cyclic voltammogram (CV) obtained in the absence of NAD + (Figure 1 , solid line) exhibits quasi-reversible redox peaks at approximately +140 mV (vs. SCE) and a peak separation of 30 mV (vs. SCE), which are attributed to the ferrocene pendant of the FcMe 2 -LPEI redox polymer. A significant oxidative catalytic signal is observed in presence of 5 mM NAD + with an approximate onset potential of -70 mV (vs. SCE), where NAD + acts as the cofactor of ChDH and an intermediary electron mediator between ChDH and DH. This signal confirms the bioelectrocatalytic oxidation of cholesterol by ChDH immobilized at the electrode surface, where NADH is oxidized by DH and subsequent MET takes place by FcMe 2 -LPEI. The ability of DH to oxidize NADH (using the FcMe 2 -LPEI redox polymer as an electron mediator) is demonstrated within the Supporting Information ( Figure S1 ). Control experiments were performed under identical conditions, although inactive DH that had been deactivated by heat-treatment replaced active DH. The absence of a significant oxidative catalytic current confirms that all components are required for cholesterol oxidation by this bilayer bioelectrode ( Figure  S2 , Supporting Information). Thereby, these results describe efficient bioelectrocatalytic oxidation of cholesterol through the use of MET from ChDH to the electrode, highlighting the advantage of this enzyme compared to ChOx (commonly associated with the electro-oxidation of electro-reduction of H 2 O 2 ).
Steady state experiments of the ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI bioanode were evaluated by injecting increasing concentrations of cholesterol while the bilayer bioelectrodes were poised at a potential of +300 mV (vs. SCE) (Figure 2) . The stock solution of cholesterol used to make substrate injections also contained an equal concentration of Triton X-100 and NAD + , in order to maintain their concentrations throughout the experiment. The results were analyzed using the Michaelis-Menten model (by nonlinear regression), yielding an apparent Michaelis constant (K M app ) of 1.19 ± 0.12 mM cholesterol Calibration curve (solid circles) for cholesterol oxidation at the ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI bilayer bioelectrode, obtained by performing amperometric i-t analysis at +300 mV (vs. SCE) in 100 mM citrate/phosphate buffer (pH 7.5) in the presence of 5 mM NAD + . Increases in current were due to injections of cholesterol from a stock of 15 mM of cholesterol containing 15% Triton X-100. Control experiments were performed using complete bioelectrodes with either denatured DH (hollow circles) or denatured ChDH (red circles) in place of their active counterparts. All electrodes were prepared on Toray carbon paper and evaluated in triplicate (error bars = SD).
and a maximum velocity (j max ) of 48.9 ± 1.7 μA cm −2 . The j max is much higher than those reported with bioanodes based on mediated ChOx. 20, [27] [28] [29] The control experiment performed with denatured DH exhibited an oxidation background due to the ability (albeit inefficient) of Toray carbon paper to oxidize NADH at +300 mV (vs. SCE). This background represents approximately 16% of the catalytic current obtained with active DH. Additionally, control experiments were performed using the complete bioelectrode setup although denatured ChDH was used in the place of active ChDH. As demonstrated in Figure 2 , no significant bioelectrocatalytic oxidative current is observed in the absence of active ChDH. Amperometric i-t curves for the active and control experiments are provided within the Supporting Information ( Figure S3) .
The results of the steady state experiments indicate a linear response range from 5 μM to 200 μM cholesterol, with a sensitivity of 60.12 mA cm −2 M −1 . These values identify this ChDH-based bioelectrode as a promising alternative to common ChOx bioelectrodes used in the electrochemical cholesterol biosensor literature. Compared to recent literature examples (Table I) , these values identify the ChDH/C 8 -LPEI/DH/FcMe 2 LPEI bioanode as an interesting proof of concept for the development of electrochemical cholesterol biosensors that does not produce H 2 O 2 or require its subsequent oxidation. Additionally, the O 2 -independent nature of this bioelectrode architecture ensures improved repeatability where dissolved O 2 concentration variation between samples is problematic for traditional ChOx-based bioelectrodes.
Enzymatic fuel cell (EFC) characterization.-In bioelectrochemistry, cholesterol is rarely presented as a potential fuel for EFCs due to the limitation of cholesterol oxidation by ChOx bioelectrodes. From the results described above, ChDH is proposed as a promising enzyme for cholesterol EFC development. The ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI bioanodes and BOx biocathodes were combined into a complete cholesterol/O 2 membrane-less and peroxide-free EFC. BOx biocathodes were prepared with anthracene-functionalized multi-walled carbon nanotubes (Ac-MWCNTs), where the anthracene functionalities facilitate the orientation of the T1 Cu center of BOx and favor direct electron transfer (DET). 35 The resulting biocathodes are able to undergo a 4e
− reduction of O 2 to H 2 O without the need for an electron mediator. The cholesterol/O 2 EFCs were evaluated by galvanostatic discharge under quiescent conditions in citrate/phosphate buffer pH 7.5 or in human serum; bioanodes and biocathodes were prepared on 1 cm 2 Toray carbon paper electrodes ( Figure 3 ). In buffer supplemented with 5 mM cholesterol and 5 mM NAD + , the EFCs are able to generate a maximum power (P max ) of 20.3 ± 0.49 μW cm −2 at a potential of 267 ± 8 mV, with an associated open circuit potential (OCP) of 592 ± 5 mV. This peroxide-free EFC is presented as an interesting alternative to the only other reported self -powered cholesterol biosensor, yielding a maximum power of approximately 11 μW cm −2 at a lower voltage of approximately 50 mV. 20 Moreover, the same EFCs were tested in human serum (naturally containing free cholesterol) in order to investigate its suitability within implantable applications. An OCP of 428.7 mV ± 5.5 and associated P max of 9.02 μW ± 0.54 were obtained with the EFCs operating in serum spiked with 5 mM NAD + and already containing an estimated total cholesterol concentration between 190-210 mg dL −1 (5.1-5.7 mM). This cholesterol concentration reflects the sum of the free cholesterol concentration (generally around 30%, thus approximately 1.7 mM) and the lipoprotein containing cholesterol (very low density lipoprotein (VLDL) and high density lipoprotein (HDL)). Therefore, the lower power density could be explained by a lower concentration of free cholesterol in human serum compared to the concentration of cholesterol employed within buffer (5 mM); additionally, BOx has been shown to exhibit good biocompatibility with experiments performed in human serum. 5 A decrease in OCP was also observed between the EFCs operating in buffer and in human serum. Activation losses such as these could be due to mild enzymatic deactivation by compounds found within the serum (such as urate or halide ions). It is also possible that other redox-active species present within human serum may be affecting the potentials at the bioanode and/or biocathode. Additionally, EFC controls within buffer and human serum were performed with denatured ChDH ( Figures S4 and S5 , Supporting Information); under both conditions, a fast discharge can be observed confirming that the bioelectrocatalytic reaction with ChDH is required to fuel the EFC with cholesterol.
Conclusions
This study has shown that ChDH can be used for the bioelectrocatalytic oxidation of cholesterol, independent of O 2 and its concomitant production of H 2 O 2 . This enzyme has been combined with DH using a bilayer immobilization approach at the electrode surface involving a ferrocene redox polymer. Therefore, these bioanodes (ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI) operate through a MET system that incorporates in intermediary NADH-oxidizing enzyme (DH). Voltammetric and amperometric measurements have been performed in order to characterize the two layers, demonstrating that ChDH is a promising alternative to the almost exclusively employed ChOx in the context of electrochemical biosensor. Finally, the ChDH/C 8 -LPEI/DH/FcMe 2 -LPEI bioanodes have been combined with BOx O 2 -reducing biocathodes to yield a complete cholesterol/O 2 membrane-less and peroxideless EFC configuration. This EFC configuration is a promising prototype for self-powered cholesterol biosensors. This work has shown that a NAD-dependent dehydrogenase could be an alternative to ChOx for cholesterol EFC and biosensor applications. Technologies that employ O 2 -dependent ChOx and quantify cholesterol as a function of H 2 O 2 are inherently limited by the availability of O 2 , and O 2 concentration variation between samples greatly affects reproducibility. Thus, our O 2 -independent configuration offers a great advantage where the presence or absence of O 2 does not affect or alter the operation of the bioanode. Future work will investigate strategies for immobilizing the cofactor NAD/NADH within the bioanode structure for implantable applications.
